Document is current
Any future updates will be listed below
-
Authors
Banach, Maciej https://orcid.org/0000-0001-6690-6874
Norata, Giuseppe Danilo https://orcid.org/0000-0002-6081-1257
-
Funding
Funding for this research was provided by:
Università degli Studi di Milano
- License Information
-
More Information
Article History
Accepted: 20 September 2023
First Online: 13 October 2023
Declarations
:
: MB: speaker’s bureau: Amgen, Daichii Sankyo, Kogen, KRKA, Pfizer, Polpharma, Mylan/Viatris, Novartis, Novo-Nordisk, Sanofi-Aventis, Teva, Zentiva; consultant to Adamed, Amgen, Daichii Sankyo, Esperion, NewAmsterdam, Novartis, Novo-Nordisk, Polfarmex, Sanofi-Aventis; Grants from Amgen, Daichii Sankyo, Mylan/Viatris, and Sanofi; CMO at Nomi Biotech Corporation; CMDO at the Longevity group (LU). GDN reports Grants from Amgen, Novartis, Pfizer; consultant to Merck and Viatris.
: This article does not contain any studies with human or animal subjects performed by any of the authors.
